Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Bator
AddedFeb 16, 2024
UpdatedMay 31, 2026
Michael Bator

Michael Bator

Board Member, CytoSorbents

CrunchbaseLinkedInThe Org

Michael Bator's Career

CytoSorbents
CytoSorbents

Monmouth Junction, NJ, US

Board Member· Board
3DBio
3DBio

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Bator's Career

CytoSorbents
CytoSorbents
Public$39.8M1982014Monmouth Junction, NJ, US
Board Member· Board

Leadership at CytoSorbents

Edward 'Ed' JonesEdward 'Ed' JonesBoard Member
Phillip P. ChanPhillip P. ChanBoard Member
Frank ClarkFrank ClarkFounder
Robert BartlettRobert BartlettBoard Member

Similar to CytoSorbents

SeaStar MedicalSeaStar MedicalAnn Arbor, MI, USMedical Devicesest. 2007SeaStar MedicalAnn Arbor, MI, US · est. 2007

CytoPherx Inc. offers proprietary medical devices for treating inflammation-based diseases.

Series C · $50.2M5
Immutrix TherapeuticsImmutrix TherapeuticsRapid City, SD, USMedical Devicesest. 2009Immutrix TherapeuticsRapid City, SD, US · est. 2009

Immutrix Therapeutics: Innovating blood cleansing with proprietary tech to remove toxins and mediators.

Angel · $3.1M30
Halcyon BiomedicalHalcyon BiomedicalFriendswood, TX, USMedical Devicesest. 2010Halcyon BiomedicalFriendswood, TX, US · est. 2010

US-based Halcyon Biomedical innovates medical devices for purifying stored blood, established in 2013.

Pre-Seed · $1.1M1
Path EXPath EXNashville, TN, USMedical Devicesest. 2016Path EXNashville, TN, US · est. 2016

PATH EX: Pioneering sepsis treatment through proprietary technology that selectively captures and removes bacteria from blood.

Seed · $4.8M3
3DBio
3DBio
Public$500k392014New York City, NY, US
Board Member· Board

Leadership at 3DBio

Scott J. DyllaScott J. DyllaBoard Member
Harlan WeismanHarlan WeismanBoard Member
Kevin SlawinKevin SlawinBoard Member
Daniel CohenDaniel CohenCo-Founder & CEO
Hod LipsonHod LipsonCo-Founder
Larry BonassarLarry BonassarCo-Founder

Similar to 3DBio

Precise BioPrecise BioWinston-Salem, NC, USBio-Fabricated Organsest. 2015Precise BioWinston-Salem, NC, US · est. 2015

Precise Bio: Innovating in regenerative medicine through 4D bio-fabrication of tissues and organs.

Series A · $27.5M33
3D Biotek3D BiotekNorth Brunswick, NJ, USBioprinting, Cell Cultureest. 20073D BiotekNorth Brunswick, NJ, US · est. 2007

3D Biotek LLC: A biotech firm specializing in manufacturing 3D cell culture devices since 2007.

Angel · $225k4
SunP BiotechSunP BiotechCherry Hill, NJ, USBioprinting, Tissueengineeringest. 2014SunP BiotechCherry Hill, NJ, US · est. 2014

SunP Biotech: Pioneering in 3D bio-printing and tissue engineering for advanced drug discovery and testing.

Series A · $4.3M30

Michael Bator's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Michael Bator

John HoJohn HoBoard Member · SolchromaADELE CIRONE OLIVAADELE CIRONE OLIVABoard Member · Tela BioChris HarnedChris HarnedBoard Member · QuadMichael BruunMichael BruunBoard Member · NorthvoltTodd BrightTodd BrightBoard Member · Seaborn NetworksMatt RiekeMatt RiekeBoard Member · Asensus Surgical